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1. Introduction 
The Extracellular signal-related kinase (ERK) Mitogen-activated protein kinase (MAPK) 
pathway is a signaling cascade that is activated by various extracellular stimuli including 
fibroblast growth factors. The ERK MAPK pathway has recently been shown to play critical 
roles in skeletal development. A number of human skeletal syndromes have been shown to 
result from mutations in this pathway. These include Noonan, Costello, and cardio-facio-
cutaneous syndromes (Aoki et al., 2005; Pandit et al., 2007; Rodriguez-Viciana et al., 2006). In 
addition, activating mutations in FGFR2 cause craniosynostosis syndromes such as Apert and 
Crouzon syndromes, while activating mutations in fibroblast growth factor receptor 3 (FGFR3) 
are responsible for the most common forms of human dwarfism, achondroplasia, 
thanatophoric dysplasia, and hypochondroplasia (Bellus et al., 1995; Jabs et al., 1994; Rousseau 
et al., 1994, 1995; Rutland et al., 1995; Shiang et al., 1994; Wilcox et al., 1998; Wilkie et al., 1995).  
Although a number of in vitro experiments indicated profound effects of the ERK MAPK 
pathway on chondrocyte and osteoblast phenotype, sometimes conflicting results were 
reported presumably due to variable culture conditions (Bobick & Kulyk, 2008; Schindeler & 
Little, 2006), and the roles of the ERK MAPK pathway in vivo remained elusive. Therefore, 
to examine the role of ERK MAPK in skeletal development, we used both gain-of-function 
and loss-of-function approaches to activate or inactivate the ERK MAPK pathway in skeletal 
tissues of genetically engineered mice. We used the Cre-loxP system to inactivate ERK1 and 
ERK2 in skeletal tissues (Logan et al., 2002; Matsushita et al., 2009a). By using the Prx1-Cre 
transgene, mice lacking ERK1 and ERK2 in the limb and head mesenchyme were created. 
We also generated a loss of function model in chondrocytes by using the Col2a1-Cre 
transgene (Matsushita et al., 2009a; Ovchinnikov et al., 2000). To induce postnatal 
inactivation of ERK1 and ERK2 in chondrocytes, we used the Col2a1-CreER transgene to 
express a tamoxifen-inducible form of Cre recombinase (Nakamura et al., 2006; Sebastian et 
al., 2011). For gain-of-function experiments, we generated Prx1-MEK1 transgenic mice that 
express a constitutively active mutant of MEK1 in undifferentiated mesenchymal cells under 
the control of a Prx1 promoter (Matsushita et al., 2009a). We also generated Col2a1-MEK1 
transgenic mice that express a constitutively active mutant of MEK1 in chondrocytes under 
the control of the regulatory sequences of Col2a1 (Murakami et al., 2004). In this review, we 
will summarize the roles of the ERK MAPK pathway in skeletal development based on our 
recent studies using genetically engineered mouse models.  
www.intechopen.com
 
Protein Kinases 
 
382 
2. Skeletal development and ossification processes 
Bone formation takes place in two major ossification processes, endochondral ossification 
and intramembranous ossification (Colnot, 2005; Hunziker, 1994; Opperman, 2000; Shapiro 
et al., 2005). Both chondrocytes and osteoblasts arise from common undifferentiated 
mesenchymal progenitor cells. In endochondral ossification, the skeletal element is formed 
as a cartilaginous template that is subsequently replaced by bone. Undifferentiated 
mesenchymal cells first aggregate to form mesenchymal condensation and differentiate into 
chondrocytes. Chondrocytes proliferate in columnar stacks to form the growth plate, then 
exit the cell cycle, and differentiate into hypertrophic chondrocytes. The cartilaginous matrix 
of hypertrophic chondrocytes is calcified and subsequently invaded by blood vessels. 
Hypertrophic chondrocytes are removed by apoptotic cell death, and the cartilaginous 
matrix is resorbed by chondroclasts/osteoclasts and replaced by trabecular bone. 
Chondroclast/osteoclast formation is supported by receptor activator of nuclear factor-
kappa B ligand (RANKL) secreted from osteoblasts and bone marrow stromal cells (Kim et 
al., 2000; Yasuda et al., 1998). In intramembranous ossification, mesenchymal cells directly 
differentiate into bone-forming osteoblasts; cortical bone is formed by osteoblasts that arise 
from the osteochondro progenitor cells in the perichondrium. The entire process of 
endochondral ossification and intramembranous ossification is under the control of various 
hormones and growth factors. These include systemic factors such as growth hormone, 
estrogen, and glucocorticoids; and local factors such as Indian hedgehog (Ihh), parathyroid 
hormone-related peptide (PTHrP), fibroblast growth factors (FGF), transforming growth 
factor- (TGF-), and bone morphogenetic proteins (BMP) (DeLise et al., 2000; van der 
Eerden et al., 2003). 
3. The ERK MAPK pathway and human syndromes 
3.1 The ERK MAPK pathway 
The ERK MAPK pathway (Fig. 1), which is activated by various stimuli in eukaryotic cells, 
transduces extracellular signals into cells and coordinates cellular responses. The MAPK 
pathways are generally organized into three kinase modules: MAPKK kinase (MAPKKK), 
MAPK kinase (MAPKK), and MAPK. MAPKKK phosphorylates and activates MAPKK, 
which in turn phosphorylates and activates MAPK. A diverse array of growth factors and 
cytokines transduce their signals through the activation of the small G protein Ras, which 
leads to the activation of the Raf members of MAPKKK, and then to the activation of 
MAPKK, MEK1 and MEK2. MEK1 and MEK2 then phosphorylate and activate MAPK, 
ERK1 and ERK2. ERK1 and ERK2 then phosphorylate various cytoplasmic and nuclear 
target proteins, ranging from cytoplasmic adaptor proteins and transcription factors to 
kinases including RSK (Cargnello & Roux, 2011; Roux & Blenis, 2004). The ERK MAPK 
pathway has been shown to mediate the intracellular signaling induced by a variety of 
growth factors such as FGFs, BMPs, and TGFs (Jun et al., 2010; Mu et al., 2011; Murakami et 
al., 2000; Osyczka & Leboy, 2005; Qureshi et al., 2005; Tuli et al., 2003).  
3.2 Human syndromes caused by mutations in the MAPK pathway 
Recently, a number of human mutations have been identified in the molecules in the MAPK 
cascade (Fig. 1). Missense activating mutations in KRAS, BRAF, MEK1, and MEK2 have 
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been identified in Cardio-facio-cutaneous syndrome (Rodriguez-Viciana et al., 2006). KRAS 
mutations have been also identified in Noonan syndrome (Schubbert et al., 2006). HRAS 
mutations cause Costello syndrome (Aoki et al., 2005), and loss-of-function mutations in 
RSK2 cause Coffin-Lowry syndrome (Trivier et al., 1996). In addition, haploinsufficient 
expression of ERK2 has been associated with DiGeorge syndrome (Newbern et al., 2008). All 
of these syndromes present with various skeletal manifestations, including short stature and 
craniofacial and limb abnormalities, underscoring the importance of the MAPK pathway in 
human skeletal development (Hanauer & Young, 2002; Hennekam, 2003; Noonan, 2006; 
Reynolds et al., 1986; van der Burgt, 2007).  
 
Fig. 1. The ERK MAPK pathway and human skeletal syndromes 
4. Genetic manipulation of molecules in the ERK MAPK pathway in mice 
To examine the role of the MAPK pathway, various mutant mice have been generated. 
Inactivation of Rsk2, a downstream kinase of the MAPK pathway, caused a widening of 
cranial sutures at birth, similar to the delayed closure of fontanelles in patients with Coffin-
Lowry syndrome (David et al., 2005; Yang et al., 2004). These observations indicate that Rsk2 
plays a critical role in osteoblast differentiation. In contrast to Rsk2-null mice, the 
inactivation of ERK, MEK, and Raf family members has provided little information 
regarding skeletal development. ERK1-null mice are viable and fertile and develop normally 
without obvious skeletal abnormalities, suggesting that ERK1 is dispensable for skeletal 
development (Pages et al., 1999; Selcher et al., 2001). In remarkable contrast, ERK2-null mice 
show early embryonic lethality at E6.5, precluding the analysis of skeletal development 
(Saba-El-Leil et al., 2003; Yao et al., 2003). Mek1-null embryos die at E10.5 due to placental 
defects, while Mek2-null mice develop normally without any obvious abnormalities 
(Belanger et al., 2003; Giroux et al., 1999). Araf-null mice show neurological and 
gastrointestinal defects, but do not show an obvious skeletal phenotype (Pritchard et al., 
1996). Braf-deficient embryos die at midgestation due to vascular defects, precluding the 
analysis of skeletal development (Wojnowski et al., 1997). Craf-null mice show placental 
defects and die at around E10.5-12.5 on the C57BL/6 and 129 backgrounds. On the outbred 
www.intechopen.com
 
Protein Kinases 
 
384 
CD1 background, two-thirds of embryos reach term and die soon after birth. These 
surviving embryos show a mild delay in ossification; however, it is not clear whether the 
observed skeletal phenotype is primarily caused by Craf deficiency in the skeletal tissues 
(Wojnowski et al., 1998). Furthermore, mice with chondrocytes deficient in both Araf and 
Braf showed normal endochondral bone development (Provot et al., 2008). These 
observations suggest that members of the ERK, MEK, and Raf family are functionally 
redundant, while some of the tissue-specific functions are not fully compensated by other 
family members. To circumvent early embryonic lethality caused by the systemic 
inactivation of the target gene, tissue-specific inactivation would be essential. Furthermore, 
the inactivation of multiple family members may be necessary to uncover the roles of ERK, 
MEK, and Raf family members in skeletal development.  
5. Inactivation of ERK1 and ERK2 in undifferentiated mesenchymal cells 
disrupts bone formation and induces ectopic cartilage formation 
Since early embryonic lethality hampered researchers from analyzing the role of the ERK 
MAPK pathway in skeletal development in vivo as described above, we used the Cre-loxP 
system to inactivate ERK1 and ERK2 in skeletal tissues. We used Prx1-Cre transgenic mice 
that express Cre recombinase under the control of the 2.4 kb Prx1 promoter (Logan et al., 
2002) to inactivate ERK1 and ERK2 in the limb and head mesenchyme (Matsushita et al., 
2009a). The Prx1 promoter has been shown to direct transgene expression in 
undifferentiated mesenchyme in the developing limb buds and head mesenchyme. The 
transgene expression is detectable as early as E10.5, and the transgene expression is confined 
to the periosteum of the long bones and tendons of the limbs at E15.5 (Logan et al., 2002). 
We analyzed ERK1-null mice and ERK2flox/flox; Prx1-Cre mice, and these mice did not show 
obvious skeletal abnormalities. Therefore, we further inactivated ERK2 in the ERK1-null 
background to totally inactivate ERK1 and ERK2 in the head and limb mesenchyme of 
mouse embryos using the Prx1-Cre transgene (Matsushita et al., 2009a). 
5.1 Inactivation of ERK1 and ERK2 in mesenchymal cells disrupts osteoblast 
differentiation 
Skeletal preparation of ERK1 -/-; ERK2 flox/flox; Prx1-Cre mutants revealed severe limb 
deformities as well as calvaria defects characterized by delayed closure of the cranial sutures 
(Fig. 2). Histological analysis of the long bones showed disruption of bone formation. These 
findings indicate that ERK1 and ERK2 play an essential role in bone formation. In situ 
hybridization analysis indicated that master osteogenic transcription factors Runx2, Osterix, 
and Atf4 were expressed at normal levels, while expression of Osteocalcin, a marker of 
mature osteoblasts, was strongly decreased in ERK1 -/-; ERK2 flox/flox; Prx1-Cre mice. These 
observations suggest that osteoblast differentiation was blocked after Runx2, Osterix, and 
Atf4 expression and before Osteocalcin expression. The impaired bone formation was 
associated with decreased beta-catenin protein levels in the periosteum, suggesting 
decreased Wnt signaling. We also found that other transcriptional regulators such as Krox20, 
Fra1, Fra2, cFos, and Cbfb were downregulated in ERK1 -/-; ERK2 flox/flox; Prx1-Cre embryos. 
While the regulatory mechanisms of osteoblast differentiation require further investigation, 
ERK1 and ERK2 are likely to control skeletal development and osteoblast differentiation 
through multiple downstream molecules. Consistent with our observation, Ge et al. reported 
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that transgenic mice that express dominant negative MEK1 under an Osteocalcin promoter 
showed delayed bone formation and reduced mineralization of calvaria, while mice that 
express a constitutively active MEK1 under the Osteocalcin promoter showed accelerated bone 
formation (Ge et al., 2007). These observations also indicated a critical role of ERK1 and ERK2 
in osteoblast differentiation. In vitro studies have also suggested that the ERK MAPK pathway 
regulates osteoblast differentiation through phosphorylation and acetylation of Runx2 (Ge et 
al., 2007; Park et al., 2010; Xiao et al., 2000, 2002). The importance of the ERK MAPK pathway 
in osteoblast differentiation in head mesenchyme was also demonstrated by Shukla et al., who 
showed that craniosynostosis in a mouse model of Apert syndrome that carries a mutation in 
Fgfr2 was prevented by the treatment of MEK1/2 inhibitor (Shukla et al., 2007). These 
observations further link the activation of the ERK MAPK pathway to the pathogenesis of 
craniosynostosis syndromes caused by activating mutations in FGFR2.  
 
Fig. 2. (A) Skeletal preparation after alizarin red and alcian blue staining at postnatal day 1. 
(B) Skeletal preparation after alizarin red and alcian blue staining at postnatal day 5. 
5.2 Inactivation of ERK1 and ERK2 disrupts osteocyte differentiation 
Osteoblasts undergo sequential steps of differentiation and subsequently become embedded 
in bone matrix as osteocytes. Osteocytes function as a mechanosensor in the bone and 
secrete dentin matrix protein 1 (Dmp1) and FGF23 to regulate phosphate homeostasis 
(Dallas & Bonewald, 2010; Feng et al., 2006; Tatsumi et al., 2007; Xiao and Quarles, 2010). 
Although ERK1-/-; ERK2flox/flox; Prx1-Cre mice showed a remarkable impairment of bone 
formation, bone-like architecture was observed in the diaphyses of long bones, and 
osteocyte-like cells were found within the bone-like matrix. Our real-time PCR and 
immunohistochemical analysis indicated a strong decrease in Dmp1 expression in the 
skeletal elements of ERK1-/-; ERK2 flox/flox; Prx1-Cre mice. Furthermore, scanning electron 
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microscopic analysis revealed that osteocytes in ERK1-/-; ERK2flox/flox; Prx1-Cre mice lack 
dendritic processes, indicating that ERK1 and ERK2 inactivation disrupts the formation of 
osteocyte-lacunar-canalicular system (Kyono et al., 2011). These observations indicate that 
ERK signaling is essential for Dmp1 expression and osteocyte differentiation.  
5.3 Inactivation of ERK1 and ERK2 in mesenchyme causes ectopic cartilage formation  
While inactivation of ERK1 and ERK2 inhibited osteoblast differentiation and bone 
formation, we found ectopic cartilage formation in the perichondrium of ERK1 -/-; ERK2 
flox/flox; Prx1-Cre mice (Fig. 3). The ectopic cartilage expressed Sox9, a transcription factor for 
chondrocyte differentiation, and Col2a1, the gene for type II collagen (Matsushita et al., 
2009a). These findings suggest that inactivation of ERK1 and ERK2 in mesenchyme inhibited 
osteoblast differentiation and promoted chondrocyte differentiation. Ectopic cartilage 
formation has been also reported in the perichondrium of Osterix-null mice (Nakashima et 
al., 2002) and in the perichondrium of mice in which beta-catenin was disrupted in 
mesenchymal cells (Day et al., 2005; Hill et al., 2005). While normal Osterix expression was 
observed in ERK1 -/-; ERK2 flox/flox; Prx1-Cre mice, beta-catenin protein levels were decreased 
in the perichondrium of ERK1 -/-; ERK2 flox/flox; Prx1-Cre mice. These observations suggest a 
role for decreased beta-catenin in the ectopic cartilage formation in the perichondrium. 
 
Fig. 3. Hematoxylin, eosin and alcian blue staining of femur of newborn mice. Arrows 
indicate ectopic cartilage formation in the perichondrium of ERK1-/-;ERK2flox/flox;Prx1-Cre 
mice. 
6. Constitutive activation of MEK1 in undifferentiated mesenchymal cells 
leads to increased bone formation and inhibition of cartilage formation 
As a complementary experiment, we generated Prx1-MEK1 transgenic mice that express a 
constitutively active mutant of MEK1 in undifferentiated limb and cranial mesenchyme 
(Matsushita et al., 2009a). Prx1-MEK1 mice showed a marked increase in cortical bone 
formation, fusion of long bones as well as carpal and tarsal bones, and an accelerated 
closure of cranial sutures, mimicking the phenotype of human craniosynostosis syndromes 
caused by activating mutations in FGFR2. The increase in bone formation was associated 
with increased expression of osteoblast markers, such as Runx2, Osterix, Bsp, and Osteocalcin. 
In contrast, cartilage formation was inhibited in Prx1-MEK1 transgenic mice. There was a 
clear delay in the formation of cartilage anlagen as well as a decrease in anlagen size. In 
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Table 1. Genetically engineered mouse models with increased or decreased ERK MAPK 
signaling in skeletal cells. CA MEK1/Prx1, Transgenic mice that express a constitutively 
active mutant of MEK1 under the control of a Prx1 promoter. CA MEK1/Col2a1, Transgenic 
mice that express a constitutively active mutant of MEK1 under the control of a Col2a1 
promoter. DN MEK1/Osteocalcin, Transgenic mice that express a dominant-negative 
mutant of MEK1 under the control of an Osteocalcin promoter. CA MEK1/Osteocalcin, 
Transgenic mice that express a constitutively active mutant of MEK1 under the control of an 
Osteocalcin promoter. 
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addition, expression of Col2a1 was reduced in the cartilage primordia. These observations 
are consistent with the phenotypes of ERK1 -/-; ERK2 flox/flox; Prx1-Cre mice, in which the lack 
of ERK1 and ERK2 disrupts bone formation and induces ectopic cartilage formation. These 
observations are also consistent with the in vitro studies showing inhibitory effects of the 
ERK MAPK pathway on chondrogenesis. The ERK MAPK inhibitors U0126 and PD98059 
increased the expression of Col2a1 and aggrecan in embryonic limb mesenchyme, and 
transfection of limb mesenchyme with constitutively active mutant of MEK decreased the 
activity of a Sox9-responsive Col2a1 enhancer reporter gene (Bobick & Kulyk, 2004). 
Collectively, these observations indicate that ERK MAPK signaling plays an important role 
in the lineage specification of mesenchymal cells.  
7. Inactivation of ERK1 and ERK2 in chondrocytes causes severe 
chondrodysplasia and enhances bone growth 
Type II collagen is the most abundant collagen in cartilage. Col2a1, the gene encoding the 
proalpha1(II) collagen chain, is a principal marker of chondrocyte differentiation. We created a 
loss of function model of ERK1 and ERK2 in chondrocytes by using the Col2a1-Cre transgenic 
mice that express Cre recombinase under the regulatory sequences of Col2a1 (Matsushita et al., 
2009a; Ovchinnikov et al., 2000). ERK1 -/-; ERK2 flox/flox; Col2a1-Cre mutant mice died 
immediately after birth, likely secondary to respiratory insufficiency caused by rib cage 
deformity (Matsushita et al., 2009a). To circumvent the perinatal lethality, we also used the 
Col2a1-CreER transgene to express a tamoxifen-inducible form of Cre recombinase and 
examined the role of ERK1 and ERK2 in chondrocytes during postnatal growth (Nakamura et 
al., 2006; Sebastian et al., 2011). For the gain-of-function experiments, we generated Col2a1-
MEK1 transgenic mice that express a constitutively active mutant of MEK1 in chondrocytes 
under the control of the regulatory sequences of Col2a1 (Murakami et al., 2004). 
7.1 ERK1 and ERK2 are essential for proper organization of epiphyseal cartilage 
A strong skeletal phenotype was observed in ERK1 -/-; ERK2 flox/flox; Col2a1-Cre embryos. We 
observed severe kyphotic deformities of the spine. Histological analysis of ERK1 -/-; ERK2 
flox/flox; Col2a1-Cre embryos at embryonic day 16.5 showed an absence of primary ossification 
centers in the axial skeleton and a widening of the zone of hypertrophic chondrocytes in the 
long bones (Fig. 4). In addition, disorganization of the epiphyseal cartilage with lack of 
columnar growth structures was observed in ERK1 -/-; ERK2 flox/flox; Col2a1-Cre embryos at 
embryonic day 18.5. These findings indicate that ERK1 and ERK2 are essential for the 
proper organization of the epiphyseal cartilage. 
 
Fig. 4. Hematoxylin, eosin and alcian blue staining of the tibia showed delayed formation of 
primary ossification center in ERK1 -/-; ERK2 flox/flox; Col2a1-Cre embryos at embryonic day 16.5. 
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7.2 ERK1 and ERK2 inhibit hypertrophic chondrocyte differentiation 
Both ERK1 -/-; ERK2 flox/flox; Prx1-Cre and ERK1 -/-; ERK2 flox/flox; Col2a1-Cre mice showed a 
remarkable expansion of the zone of hypertrophic chondrocytes. In both animal models, 
chondrocytes that were closer to the articular surface expressed hypertrophic chondrocyte 
marker Col10a1, suggesting premature chondrocyte hypertrophy. These observations are 
consistent with the growth plate phenotype of Col2a1-MEK1 transgenic mice that express a 
constitutively active MEK1 mutant in chondrocytes (Murakami et al., 2004). The growth 
plate of Col2a1-MEK1 transgenic mice was characterized by smaller than normal 
hypertrophic chondrocytes and narrower zone of hypertrophic chondrocytes. BrdU labeling 
of proliferating chondrocytes and subsequent identification of BrdU-labeled hypertrophic 
chondrocytes indicated reduced rate of chondrocyte hypertrophy in Col2a1-MEK1 mice. 
Collectively, these observations indicate that ERK MAPK signaling inhibits hypertrophic 
chondrocyte differentiation.  
The pronounced expansion of the zone of hypertrophic chondrocytes in ERK1 -/-; ERK2 flox/flox; 
Prx1-Cre mice was also characterized by an increase in terminally differentiated 
hypertrophic chondrocytes expressing Vegf, Mmp13, and Osteopontin, suggesting impaired 
removal of terminally differentiated hypertrophic chondrocytes. We also observed a 
decrease in TRAP-positive osteoclasts in association with reduced expression of receptor 
activator of nuclear factor-kappa B ligand (RANKL). Therefore, decreased osteoclastogenesis 
may also account for the expansion of the zone of hypertrophic chondrocytes.  
7.3 ERK1 and ERK2 inhibit growth of cartilaginous skeletal element 
A number of genetic studies have indicated the growth inhibitory role of FGFR3 signaling. 
Mice with activating mutations in Fgfr3 show a dwarf phenotype similar to the human 
syndromes of achondroplasia and thanatophoric dysplasia (Chen et al., 1999; Iwata et al., 
2000, 2001; Li et al., 1999; Naski et al., 1998; Wang et al., 1999). In contrast, Fgfr3-null mice 
show a skeletal overgrowth (Colvin et al., 1996; Deng et al., 1996). Our observations in 
genetically engineered mouse models have provided evidence indicating that the ERK 
MAPK pathway is a critical downstream effector of Fgfr3 signaling. We have shown that 
Col2a1-MEK1 transgenic mice that express a constitutively active MEK1 mutant in 
chondrocytes show an achondroplasia-like dwarf phenotype (Murakami et al., 2004). We 
have also shown that ERK1 and ERK2 inactivation in chondrocytes promotes bone growth. 
We found increased length of the proximal long bones, specifically the humerus and femur, 
of ERK1 -/-; ERK2 flox/flox; Col2a1-Cre embryos (Sebastian et al., 2011). These embryos also 
showed an increase in the width of epiphyses in the humerus and femur. Histological 
analysis of the vertebrae also showed an overgrowth of cartilage in the vertebral body. 
These observations indicate that ERK1 and ERK2 negatively regulate the growth of 
cartilaginous skeletal elements.  
8. Postnatal ERK1 and ERK2 inactivation delays synchondrosis closure and 
enlarges the spinal canal  
Our studies have indicated that FGFR3 and the MAPK pathway are important regulators of 
synchondrosis closure. In bones such as the vertebrae, sternum, pelvis, and bones in the 
cranial base, a synchondrosis—a growth plate-like cartilaginous structure—connects the 
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ossification centers and contributes to the bone growth. During postnatal skeletal 
development, the width of synchondroses reduces with age. Ossification centers eventually 
unite when synchondroses close. Histologically, a synchondrosis consists of two opposed 
growth plates with a common zone of resting chondrocytes (Fig. 5A). We have found 
premature synchondrosis closure in the vertebrae and cranial base of human samples of 
achondroplasia and thanatophoric dysplasia (Matsushita et al., 2009b). In addition, we have 
also observed premature synchondrosis closure in a mouse model of achondroplasia and 
Col2a1-MEK1 transgenic mice that express a constitutively active MEK1 mutant in 
chondrocytes (Fig. 5B). Because growth at the synchondrosis determines the final dimension 
and shape of the endochondral skeletons, premature synchondrosis closure should play a 
critical role in the development of spinal canal stenosis that is frequently seen in patients with 
achondroplasia. 
Since increased Fgfr3 and MEK1 signaling accelerates synchondrosis closure, we 
hypothesized that ERK1 and ERK2 inactivation delays synchondrosis closure and enlarges 
the spinal canal. To test this hypothesis, we inactivated ERK2 in chondrocytes of ERK1-null 
 
Fig. 5. (A) Spheno-occipital synchondrosis of a 4-day-old wild type mouse. HZ; 
hypertrophic zone. PZ; proliferation zone. RZ; resting zone. (B) Thoracic spine of wild type 
and Col2a1-MEK1 transgenic mice at postnatal day 4. Arrows indicate prematurely closing 
synchondroses. Wt; wild type. 
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mice using the Col2a1-CreER transgene (Sebastian et al., 2011). Tamoxifen injection into ERK1 -/-; 
ERK2 flox/flox; Col2a1-CreER mice resulted in 60% inhibition of ERK2 expression in the epiphyseal 
cartilage. Although these mice did not show an increased growth of the long bones 
presumably due to incomplete ERK2 inactivation, we observed a significant delay in 
synchondrosis closure of the vertebrae and an increase in the cross-sectional area of vertebral 
foramen. The delayed synchondrosis closure was associated with a decreased expression of 
the endothelial marker CD31 surrounding the synchondroses, suggesting that ERK1 and ERK2 
inactivation in chondrocytes causes reduced vascular invasion. These observations indicate the 
potential of ERK1 and ERK2 as therapeutic targets for spinal canal stenosis in achondroplasia.  
9. Conclusion 
By creating and analyzing gain-of-function and loss-of-function mouse models, we have 
identified multiple roles of the ERK MAPK pathway at successive steps of skeletal 
development. In undifferentiated mesenchymal cells, ERK1 and ERK2 inactivation causes a 
block in osteoblast differentiation and induces ectopic cartilage formation. In contrast, 
increased MEK1 signaling promotes bone formation and inhibits cartilage formation. These 
observations indicate that ERK MAPK signaling plays a critical role in the lineage specification 
of mesenchymal cells (Fig. 6). ERK MAPK signaling also inhibits hypertrophic chondrocyte 
differentiation and bone growth. Furthermore, ERK MAPK signaling regulates the timing of 
growth plate and synchondrosis closure, the very last step of endochondral ossification. A 
better understanding of the roles of the ERK MAPK pathway in skeletal tissues will lead to 
new insights in skeletal development and the treatment of various skeletal disorders.  
 
Fig. 6. Proposed model of the role of ERK1 and ERK2 in the regulation of osteoblast and 
chondrocyte differentiation. 
10. Acknowledgments  
We thank Ms. Valerie Schmedlen for editorial assistance. Work in the laboratory of the authors 
was supported by Arthritis Investigator Award of the Arthritis Foundation, March of Dimes 
Birth Defects Foundation, and NIH grants R21DE017406, R01AR055556, R03DE019814 to S.M.  
11. References 
Aoki, Y., Niihori, T., Kawame, H., Kurosawa, K., Ohashi, H., Tanaka, Y., Filocamo, M., Kato, 
K., Suzuki, Y., Kure, S., & Matsubara, Y. (2005). Germline mutations in HRAS 
www.intechopen.com
 
Protein Kinases 
 
392 
proto-oncogene cause Costello syndrome. Nat Genet, Vol. 37, No. 10, pp. 1038-40, 
ISSN 1061-4036 
Belanger, L.F., Roy, S., Tremblay, M., Brott, B., Steff, A.M., Mourad, W., Hugo, P., Erikson, 
R., & Charron, J. (2003). Mek2 is dispensable for mouse growth and development. 
Mol Cell Biol, Vol. 23, No. 14, pp. 4778-87. ISSN 0270-7306  
Bellus, G.A., McIntosh, I., Smith, E.A., Aylsworth, A.S., Kaitila, I., Horton, W.A., Greenhaw, 
G.A., Hecht, J.T., & Francomano, C.A. (1995). A recurrent mutation in the tyrosine 
kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia. 
Nat Genet, Vol. 10, No. 3, pp. 357-9, ISSN 1061-4036 
Bobick, B.E., & Kulyk, W.M. (2004). The MEK-ERK signaling pathway is a negative regulator 
of cartilage-specific gene expression in embryonic limb mesenchyme. J Biol Chem, 
Vol. 279, No. 6, pp. 4588-95, ISSN 0021-9258 
Bobick, B.E., & Kulyk, W.M. (2008). Regulation of cartilage formation and maturation by 
mitogen-activated protein kinase signaling. Birth Defects Res C Embryo Today, Vol. 
84, No. 2, pp. 131-54, ISSN 1542-975X 
Cargnello, M., & Roux, P.P. (2011). Activation and function of the MAPKs and their 
substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev, Vol. 75, No. 
1, pp. 50-83, ISSN 1092-2171 
Chen, L., Adar, R., Yang, X., Monsonego, E.O., Li, C., Hauschka, P.V., Yayon, A., & Deng, 
C.X. (1999). Gly369Cys mutation in mouse FGFR3 causes achondroplasia by 
affecting both chondrogenesis and osteogenesis. J Clin Invest, Vol. 104, No. 11, pp. 
1517-25, ISSN 0021-9738 
Colnot, C. (2005). Cellular and molecular interactions regulating skeletogenesis. J Cell 
Biochem, Vol.95, No. 4, pp. 688–97, ISSN 0730-2313 
Colvin, J.S., Bohne, B.A., Harding, G.W., McEwen, D.G., & Ornitz, D.M. (1996). Skeletal 
overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. Nat 
Genet, Vol. 12, No. 4, pp. 390-7, ISSN 1061-4036 
Dallas, S.L., & Bonewald, L.F. (2010). Dynamics of the transition from osteoblast to 
osteocyte. Ann N Y Acad Sci, Vol. 1192, pp. 437-43, ISSN 0077-8923 
David, J.P., Mehic, D., Bakiri, L., Schilling, A.F., Mandic, V., Priemel, M., Idarraga, M.H., 
Reschke, M.O., Hoffmann, O., Amling, M., & Wagner, E.F. (2005). Essential role of 
RSK2 in c-Fos-dependent osteosarcoma development. J Clin Invest, Vol. 115, No. 3, 
pp. 664-72, ISSN 0021-9738 
Day, T.F., Guo, X., Garrett-Beal, L., & Yang, Y. (2005). Wnt/beta-catenin signaling in 
mesenchymal progenitors controls osteoblast and chondrocyte differentiation 
during vertebrate skeletogenesis. Dev Cell, Vol. 8, No. 5, pp. 739–50, ISSN 1534-5807 
DeLise, A.M., Fischer, L., & Tuan, R.S. (2000). Cellular interactions and signaling in cartilage 
development. Osteoarthritis Cartilage, Vol. 8, No. 5, pp. 309-34, ISSN1063-4584 
Deng, C., Wynshaw-Boris, A., Zhou, F., Kuo, A., & Leder, P. (1996). Fibroblast growth factor 
receptor 3 is a negative regulator of bone growth. Cell, Vol. 84, No. 6, pp. 911-21, 
ISSN 0092-8674 
Feng, J.Q., Ward, L.M., Liu, S., Lu, Y., Xie, Y., Yuan, B., Yu, X., Rauch, F., Davis, S.I., Zhang, 
S., Rios, H., Drezner, M.K., Quarles, L.D., Bonewald, L.F., & White, K.E. (2006). Loss 
www.intechopen.com
 
The ERK MAPK Pathway in Bone and Cartilage Formation 
 
393 
of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in 
mineral metabolism. Nat Genet, Vol. 38, No. 11, pp. 1310-5, ISSN 1061-4036 
Ge, C., Xiao, G., Jiang, D., & Franceschi, R.T. (2007). Critical role of the extracellular signal-
regulated kinase-MAPK pathway in osteoblast differentiation and skeletal 
development. J Cell Biol, Vol. 176, No. 5, pp. 709-18, ISSN 0021-9525 
Giroux, S., Tremblay, M., Bernard, D., Cardin-Girard, J.F., Aubry, S., Larouche, L., Rousseau, 
S., Huot, J., Landry, J., Jeannotte, L., & Charron, J. (1999). Embryonic death of 
Mek1-deficient mice reveals a role for this kinase in angiogenesis in the 
labyrinthine region of the placenta. Curr Biol, Vol. 9, No. 7, pp. 369-72, ISSN 0960-
9822 
Hanauer, A., & Young, I.D. (2002). Coffin-Lowry syndrome: clinical and molecular features. 
J Med Genet, Vol. 39, No. 10, pp. 705-13, Review, ISSN 0022-2593 
Hennekam, R.C. (2003). Costello syndrome: an overview. Am J Med Genet C Semin Med 
Genet, Vol. 117C, No. 1, pp. 42-8, Review, ISSN 1552-4868 
Hill, T.P., Später, D., Taketo, M.M., Birchmeier, W., & Hartmann, C. (2005). Canonical 
Wnt/beta-catenin signaling prevents osteoblasts from differentiating into 
chondrocytes. Dev Cell, Vol. 8, No. 5, pp. 727–38, ISSN 1534-5807 
Hunziker, E.B. (1994). Mechanism of longitudinal bone growth and its regulation by growth 
plate chondrocytes. Microsc Res Tech, Vol. 28, No. 6, pp. 505–19, ISSN 1059-910X 
Iwata, T., Chen, L., Li, C., Ovchinnikov, D.A., Behringer, R.R., Francomano, C.A., & Deng, 
C.X. (2000). A neonatal lethal mutation in FGFR3 uncouples proliferation and 
differentiation of growth plate chondrocytes in embryos. Hum Mol Genet, Vol. 9, 
No. 11, pp. 1603-13, ISSN 0964-6906 
Iwata, T., Li, C.L., Deng, C.X., & Francomano, C.A. (2001). Highly activated Fgfr3 with the 
K644M mutation causes prolonged survival in severe dwarf mice. Hum Mol Genet, 
Vol. 10, No. 12, pp. 1255-64. ISSN 0964-6906 
Jabs, E.W., Li, X., Scott, A.F., Meyers, G., Chen, W., Eccles, M., Mao, J.I., Charnas, L.R., 
Jackson, C.E., & Jaye, M. (1994). Jackson-Weiss and Crouzon syndromes are allelic 
with mutations in fibroblast growth factor receptor 2. Nat Genet, Vol. 8, No. 3, pp. 
275-9, ISSN 1061-4036 
Jun, J.H., Yoon, W.J., Seo, S.B., Woo, K.M., Kim, G.S., Ryoo, H.M., & Baek, J.H. (2010). BMP2-
activated Erk/MAP kinase stabilizes Runx2 by increasing p300 levels and histone 
acetyltransferase activity. J Biol Chem, Vol. 285, No. 47, pp. 36410-9, ISSN 0021-9258 
Kim, N., Odgren, P.R., Kim, D.K., Marks, S.C.Jr., & Choi, Y. (2000). Diverse roles of the 
tumor necrosis factor family member TRANCE in skeletal physiology revealed by 
TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE 
transgene. Proc Natl Acad Sci U S A, Vol. 97, No. 20, pp. 10905-10, ISSN 0027-8424 
Kyono, A., Avishai, N., Ouyang, Z., Landreth, G.E., & Murakami, S. (2011). FGF and ERK 
signaling coordinately regulate mineralization-related genes and play essential 
roles in osteocyte differentiation. J Bone Miner Metab, (Jun 17). ISSN 0914-8779 
Li, C., Chen, L., Iwata, T., Kitagawa, M., Fu, X.Y., & Deng, C.X. (1999). A Lys644Glu 
substitution in fibroblast growth factor receptor 3 (FGFR3) causes dwarfism in mice 
by activation of STATs and ink4 cell cycle inhibitors. Hum Mol Genet, Vol. 8, No. 1, 
pp. 35-44, ISSN 0964-6906 
www.intechopen.com
 
Protein Kinases 
 
394 
Logan, M., Martin, J.F., Nagy, A., Lobe, C., Olson, E.N., & Tabin, C.J. (2002). Expression of 
Cre Recombinase in the developing mouse limb bud driven by a Prxl enhancer. 
Genesis, Vol.33, No. 2, pp. 77-80, ISSN 1526-954X 
Matsushita, T., Chan, Y., Kawanami, A., Balmes, G., Landreth, G.E., & Murakami, S. (2009a). 
Extracellular Signal-Regulated Kinase 1 (ERK1) and ERK2 play essential roles in 
osteoblast differentiation and in supporting osteoclastogenesis. Mol Cell Biol, Vol. 
29, No. 21, pp. 5843-57, ISSN 0270-7306 
Matsushita, T., Wilcox, W.R., Chan, Y.Y., Kawanami, A., Bükülmez, H., Balmes, G., Krejci, 
P., Mekikian, P.B., Otani, K., Yamaura, I., Warman, M.L., Givol, D., & Murakami, S. 
(2009b). FGFR3 promotes synchondrosis closure and fusion of ossification centers 
through the MAPK pathway. Hum Mol Genet, Vol. 18, No. 2, pp. 227-40, ISSN 0964-
6906 
Mu, Y., Gudey, S.K., & Landström, M. (2011). Non-Smad signaling pathways. Cell Tissue Res, 
( Jun 24). 
Murakami, S., Kan, M., McKeehan, W.L., & de Crombrugghe, B. (2000). Up-regulation of the 
chondrogenic Sox9 gene by fibroblast growth factors is mediated by the mitogen-
activated protein kinase pathway. Proc Natl Acad Sci U S A, Vol. 97, No. 3, pp. 1113-
8, ISSN 0027-8424 
Murakami, S., Balmes, G., McKinney, S., Zhang, Z., Givol, D., & de Crombrugghe, B. (2004). 
Constitutive activation of MEK1 in chondrocytes causes Stat1-independent 
achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype. 
Genes Dev, Vol. 18, No. 3, pp. 290-305, ISSN 0860-9369 
Nakamura, E., Nguyen, M.T., & Mackem, S. (2006). Kinetics of tamoxifen-regulated Cre 
activity in mice using a cartilage-specific CreER(T) to assay temporal activity 
windows along the proximodistal limb skeleton. Dev Dyn, Vol. 235, No. 9, pp. 2603-
12, ISSN 1058-8388 
Nakashima, K., Zhou, X., Kunkel, G., Zhang, Z., Deng, J.M., Behringer, R.R., & de 
Crombrugghe, B. (2002). The novel zinc finger-containing transcription factor 
osterix is required for osteoblast differentiation and bone formation. Cell, Vol. 108, 
No. 1, pp. 17-29, ISSN 0092-8674 
Naski, M.C., Colvin, J.S., Coffin, J.D., & Ornitz, D.M. (1998). Repression of hedgehog 
signaling and BMP4 expression in growth plate cartilage by fibroblast growth 
factor receptor 3. Development, Vol. 125, No. 24, pp. 4977-88, ISSN 1011-6370 
Newbern, J., Zhong, J., Wickramasinghe, R.S., Li, X., Wu, Y., Samuels, I., Cherosky, N., 
Karlo, J.C., O'Loughlin, B., Wikenheiser, J., Gargesha, M., Doughman, Y.Q., 
Charron, J., Ginty, D.D., Watanabe, M., Saitta, S.C., Snider, W.D., & Landreth, G.E. 
(2008). Mouse and human phenotypes indicate a critical conserved role for ERK2 
signaling in neural crest development. Proc Natl Acad Sci U S A, Vol. 105, No. 44, 
pp. 17115-20, ISSN 0027-8424 
Noonan, J.A. (2006). Noonan syndrome and related disorders: Alterations in growth and 
puberty. Rev Endocr Metab Disord, Vol. 7, No. 4, pp. 251-5, ISSN 1389-9155 
Opperman, L.A. (2000). Cranial sutures as intramembranous bone growth sites. Dev Dyn, 
Vol. 219, No. 4, pp. 472–85, ISSN 1058-8388 
www.intechopen.com
 
The ERK MAPK Pathway in Bone and Cartilage Formation 
 
395 
Osyczka, A.M., & Leboy, P.S. (2005). Bone morphogenetic protein regulation of early 
osteoblast genes in human marrow stromal cells is mediated by extracellular 
signal-regulated kinase and phosphatidylinositol 3-kinase signaling. Endocrinology, 
Vol. 146, No. 8, pp. 3428-37, ISSN 0013-7227 
Ovchinnikov, D.A., Deng, J.M., Ogunrinu, G., & Behringer, R.R. (2000). Col2a1-directed 
expression of Cre recombinase in differentiating chondrocytes in transgenic mice. 
Genesis, Vol. 26, No. 2, pp. 145-6, ISSN 1526-954X 
Pages, G., Guerin, S., Grall, D., Bonino, F., Smith, A., Anjuere, F., Auberger, P., & 
Pouyssegur, J. (1999). Defective thymocyte maturation in p44 MAP kinase (Erk 1) 
knockout mice. Science, Vol. 286, No. 5443, pp. 1374-7, ISSN 0036-8075 
Pandit, B., Sarkozy, A., Pennacchio, L.A., Carta, C., Oishi, K., Martinelli, S., Pogna, E.A., 
Schackwitz, W., Ustaszewska, A., Landstrom, A., Bos, J.M., Ommen, S.R., Esposito, 
G., Lepri, F., Faul, C., Mundel, P., López Siguero, J.P., Tenconi, R., Selicorni, A., 
Rossi, C., Mazzanti, L., Torrente, I., Marino, B., Digilio, M.C., Zampino, G., 
Ackerman, M.J., Dallapiccola, B., Tartaglia, M., & Gelb, B.D. (2007). Gain-of-
function RAF1 mutations cause Noonan and LEOPARD syndromes with 
hypertrophic cardiomyopathy. Nat Genet, Vol. 39, No. 8, pp. 1007-12, ISSN 1061-
4036 
Park, O.J., Kim, H.J., Woo, K.M., Baek, J.H., & Ryoo, H.M. (2010). FGF2-activated ERK 
mitogen-activated protein kinase enhances Runx2 acetylation and stabilization. J 
Biol Chem, Vol. 285, No. 6, pp. 3568-74, ISSN 0021-9258 
Pritchard, C.A., Bolin, L., Slattery, R., Murray, R., & McMahon, M. (1996). Post-natal 
lethality and neurological and gastrointestinal defects in mice with targeted 
disruption of the A-Raf protein kinase gene. Curr Biol, Vol. 6, No. 5, pp. 614-7, ISSN 
0960-9822 
Provot, S., Nachtrab, G., Paruch, J., Chen, A.P., Silva, A., & Kronenberg, H.M. (2008). A-raf 
and B-raf are dispensable for normal endochondral bone development, and 
parathyroid hormone-related peptide suppresses extracellular signal-regulated 
kinase activation in hypertrophic chondrocytes. Mol Cell Biol, Vol. 28, No. 1, pp. 
344-57, ISSN 0270-7306 
Qureshi, H.Y., Sylvester, J., El Mabrouk, M., & Zafarullah, M. (2005). TGF-beta-induced 
expression of tissue inhibitor of metalloproteinases-3 gene in chondrocytes is 
mediated by extracellular signal-regulated kinase pathway and Sp1 transcription 
factor. J Cell Physiol, Vol. 203, No. 2, pp. 345-52, ISSN 0021-9541 
Reynolds, J.F., Neri, G., Herrmann, J.P., Blumberg, B., Coldwell, J.G., Miles, P.V., & Opitz, 
J.M. (1986). New multiple congenital anomalies/mental retardation syndrome with 
cardio-facio-cutaneous involvement--the CFC syndrome. Am J Med Genet, Vol. 25, 
No. 3, pp. 413-27, ISSN 1552-4833 
Rodriguez-Viciana, P., Tetsu, O., Tidyman, W.E., Estep, A.L., Conger, B.A., Santa Cruz, M., 
McCormick, F., & Rauen, K.A. (2006). Germline Mutations in Genes within the 
MAPK Pathway Cause Cardio-facio-cutaneous Syndrome. Science, Vol. 311, No. 
5765, pp. 1287-90, ISSN 0036-8075 
Rousseau, F., Bonaventure, J., Legeai-Mallet, L., Pelet, A., Rozet, J.M., Maroteaux, P., Le 
Merrer, M., & Munnich, A. (1994). Mutations in the gene encoding fibroblast 
www.intechopen.com
 
Protein Kinases 
 
396 
growth factor receptor-3 in achondroplasia. Nature, Vol. 371, No. 6494, pp.252-4, 
ISSN 0028-0836 
Rousseau, F., Saugier, P., Le Merrer, M., Munnich, A., Delezoide, A.L., Maroteaux, P., 
Bonaventure, J., Narcy, F., & Sanak, M. (1995). Stop codon FGFR3 mutations in 
thanatophoric dwarfism type 1. Nat Genet, Vol. 10, No. 1, pp. 11-2, ISSN 1061-4036 
Roux, P.P., & Blenis, J. (2004). ERK and p38 MAPK-activated protein kinases: a family of 
protein kinases with diverse biological functions. Microbiol Mol Biol Rev, Vol. 68, 
No. 2, pp. 320-44, ISSN 1092-2171 
Rutland, P., Pulleyn, L.J., Reardon, W., Baraitser, M., Hayward, R., Jones, B., Malcolm, S., 
Winter, R.M., Oldridge, M., Slaney, S.F., Poole, M.D., & Wilkie A.O.M. (1995). 
Identical mutations in the FGFR2 gene cause both Pfeiffer and Crouzon syndrome 
phenotypes. Nat Genet, Vol. 9, No. 2, 173-6, ISSN 1061-4036 
Saba-El-Leil, M.K., Vella, F.D., Vernay, B., Voisin, L., Chen, L., Labrecque, N., Ang, S.L., & 
Meloche, S. (2003). An essential function of the mitogen-activated protein kinase 
Erk2 in mouse trophoblast development. EMBO Rep, Vol. 4, No. 2, pp. 964-8, ISSN 
1469-221X 
Schindeler, A., & Little, D.G. (2006). Ras-MAPK signaling in osteogenic differentiation: 
friend or foe? J Bone Miner Res, Vol. 21, No. 9, pp. 1331-8, ISSN 0914-8779 
Schubbert, S., Zenker, M., Rowe, S.L., Boll, S., Klein, C., Bollag, G., van der Burgt, I., 
Musante, L., Kalscheuer, V., Wehner, L.E., Nguyen, H., West, B., Zhang, K.Y., 
Sistermans, E., Rauch, A., Niemeyer, C.M., Shannon, K., & Kratz, C.P. (2006). 
Germline KRAS mutations cause Noonan syndrome. Nat Genet, Vol. 38, No. 3, pp. 
331-6, ISSN 1061-4036 
Sebastian, A., Matsushita, T., Kawanami, A., Mackem, S., Landreth, G., & Murakami S. 
(2011). Genetic inactivation of ERK1 and ERK2 in chondrocytes promotes bone 
growth and enlarges the spinal canal. J Orthop Res, Vol. 29, No. 3, pp. 375-9, ISSN 
0736-0266 
Selcher, J.C., Nekrasova, T., Paylor, R., Landreth, G.E., & Sweatt, J.D. (2001). Mice lacking 
the ERK1 isoform of MAP kinase are unimpaired in emotional learning. Learn Mem, 
Vol. 8, No. 1, pp. 11-9, ISSN 1072-0502 
Shapiro, I.M., Adams, C.S., Freeman, T. & Srinivas, V. (2005). Fate of the hypertrophic 
chondrocyte: microenvironmental perspectives on apoptosis and survival in the 
epiphyseal growth plate. Birth Defects Res. C, Vol. 75, No. 4, pp. 330–9, ISSN 1542-
975X 
Shiang, R., Thompson, L.M., Zhu, Y.Z., Church, D.M., Fielder, T.J., Bocian, M., Winokur, 
S.T., & Wasmuth, J.J. (1994). Mutations in the transmembrane domain of FGFR3 
cause the most common genetic form of dwarfism, achondroplasia. Cell, Vol. 78, 
No. 2, pp. 335-42, ISSN 0092-8674 
Shukla, V., Coumoul, X., Wang, R.H., Kim, H.S., & Deng, C.X. (2007). RNA interference and 
inhibition of MEK-ERK signaling prevent abnormal skeletal phenotypes in a mouse 
model of craniosynostosis. Nat Genet, Vol. 39, No. 9, pp. 1145-50, ISSN 1061-4036 
Tatsumi, S., Ishii, K., Amizuka, N., Li, M., Kobayashi, T., Kohno, K., Ito, M., Takeshita, S., & 
Ikeda, K. (2007). Targeted ablation of osteocytes induces osteoporosis with 
www.intechopen.com
 
The ERK MAPK Pathway in Bone and Cartilage Formation 
 
397 
defective mechanotransduction. Cell Metab, Vol. 5, No. 6, pp. 464-75, ISSN 1550-
4131 
Trivier, E., De Cesare, D., Jacquot, S., Pannetier, S., Zackai, E., Young, I., Mandel, J.L., 
Sassone-Corsi, P., & Hanauer, A. (1996). Mutations in the kinase Rsk-2 associated 
with Coffin-Lowry syndrome. Nature, Vol. 384, No. 1, pp. 567-70, ISSN 0028-0836 
Tuli, R., Tuli, S., Nandi, S., Huang, X., Manner, P.A., Hozack, W.J., Danielson, K.G., Hall, 
D.J., & Tuan, R.S. (2003). Transforming growth factor-beta-mediated 
chondrogenesis of human mesenchymal progenitor cells involves N-cadherin and 
mitogen-activated protein kinase and Wnt signaling cross-talk. J Biol Chem, Vol. 
278, No. 42, pp. 41227-36, ISSN 0021-9258 
van der Burgt, I. (2007). Noonan syndrome. Orphanet J Rare Dis, Vol. 2, pp. 4, ISSN 1750-
1172  
van der Eerden, B.C., Karperien, M., & Wit, J.M. (2003). Systemic and local regulation of the 
growth plate. Endocr Rev, Vol. 24, No. 6, pp. 782-801, ISSN 0163-769X 
Wang, Y., Spatz, M.K., Kannan, K., Hayk, H., Avivi, A., Gorivodsky, M., Pines, M., Yayon, 
A., Lonai, P., & Givol, D. (1999). A mouse model for achondroplasia produced by 
targeting fibroblast growth factor receptor 3. Proc Natl Acad Sci U S A, Vol. 96, No. 
8, pp. 4455-60. ISSN 0027-8424 
Wilcox, W.R., Tavormina, P.L., Krakow, D., Kitoh, H., Lachman, R.S., Wasmuth, J.J., 
Thompson, L.M., & Rimoin, D.L. (1998). Molecular, radiologic, and histopathologic 
correlations in thanatophoric dysplasia. Am J Med Genet, Vol. 78, No. 3, pp. 274-81, 
ISSN 1552-4833 
Wilkie, A.O., Slaney, S.F., Oldridge, M., Poole, M.D., Ashworth, G.J., Hockley, A.D., 
Hayward, R.D., David, D.J., Pulleyn, L.J., Rutland, P., Malcolm, S., Winter, R.M., & 
Reardon, W. (1995). Apert syndrome results from localized mutations of FGFR2 
and is allelic with Crouzon syndrome. Nat Genet, Vol. 9, No. 2, pp. 165-72, ISSN 
1061-4036 
Wojnowski, L., Zimmer, A.M., Beck, T.W., Hahn, H., Bernal, R., Rapp, U.R., & Zimmer, A. 
(1997). Endothelial apoptosis in Braf-deficient mice. Nat Genet, Vol. 16, No. 3, pp. 
293-7, ISSN 1061-4036 
Wojnowski, L., Stancato, L.F., Zimmer, A.M., Hahn, H., Beck, T.W., Larner, A.C., Rapp, U.R., 
& Zimmer, A. (1998). Craf-1 protein kinase is essential for mouse development. 
Mech Dev, Vol. 76, No. 1-2, pp. 141-9, ISSN 0925-4773 
Xiao, G., Jiang, D., Gopalakrishnan, R., & Franceschi, R.T. (2002). Fibroblast growth factor 2 
induction of the osteocalcin gene requires MAPK activity and phosphorylation of 
the osteoblast transcription factor, Cbfa1/Runx2. J Biol Chem, Vol. 277, No. 39, pp. 
36181-7, ISSN 0021-9258 
Xiao, G., Jiang, D., Thomas, P., Benson, M.D., Guan, K., Karsenty, G., & Franceschi, R.T. 
(2000). MAPK pathways activate and phosphorylate the osteoblast-specific 
transcription factor, Cbfa1. J Biol Chem, Vol. 275, No. 6, pp. 4453-9, ISSN 0021-9258 
Xiao, Z.S., & Quarles, L.D. (2010). Role of the polycytin-primary cilia complex in bone 
development and mechanosensing. Ann N Y Acad Sci, Vol. 1192, pp. 410-21, ISSN 
0077-8923 
www.intechopen.com
 
Protein Kinases 
 
398 
Yang, X., Matsuda, K., Bialek, P., Jacquot, S., Masuoka, H.C., Schinke, T., Li, L., Brancorsini, 
S., Sassone-Corsi, P., Townes, T.M., Hanauer, A., & Karsenty, G. (2004). ATF4 is a 
substrate of RSK2 and an essential regulator of osteoblast biology; implication for 
Coffin-Lowry Syndrome. Cell, Vol. 117, No. 3, pp. 387-98, ISSN 0092-8674 
Yao, Y., Li, W., Wu, J., Germann, U.A., Su, M.S., Kuida, K., & Boucher, D.M. (2003). 
Extracellular signal-regulated kinase 2 is necessary for mesoderm differentiation. 
Proc Natl Acad Sci U S A, Vol. 100, No. 22, pp. 12759-64, ISSN 0027-8424 
Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S., 
Tomoyasu, A., Yano, K., Goto, M., Murakami, A., Tsuda, E., Morinaga, T., 
Higashio, K., Udagawa, N., Takahashi, N., & Suda, T. (1998). Osteoclast 
differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory 
factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A, Vol. 95, No. 
7, pp. 3597-602, ISSN 0027-8424 
www.intechopen.com
Protein Kinases
Edited by Dr. Gabriela Da Silva Xavier
ISBN 978-953-51-0640-1
Hard cover, 484 pages
Publisher InTech
Published online 05, June, 2012
Published in print edition June, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Proteins are the work horses of the cell. As regulators of protein function, protein kinases are involved in the
control of cellular functions via intricate signalling pathways, allowing for fine tuning of physiological functions.
This book is a collaborative effort, with contribution from experts in their respective fields, reflecting the spirit of
collaboration - across disciplines and borders - that exists in modern science. Here, we review the existing
literature and, on occasions, provide novel data on the function of protein kinases in various systems. We also
discuss the implications of these findings in the context of disease, treatment, and drug development.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Takehiko Matsushita and Shunichi Murakami (2012). The ERK MAPK Pathway in Bone and Cartilage
Formation, Protein Kinases, Dr. Gabriela Da Silva Xavier (Ed.), ISBN: 978-953-51-0640-1, InTech, Available
from: http://www.intechopen.com/books/protein-kinases/the-erk-mapk-pathway-in-bone-and-cartilage-
formation
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
